| Trial | Treatments | Patients | Method |
|---|
| POPLAR Phase 2 atezolizumab, 2016 | Atezolizumab (n=144) vs. docetaxel 75 mg/m(2) once every 3 weeks (n=143) | patients with locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Th | open label Parallel groups Sample size: 144/143 Primary endpoint: OS FU duration: phase 2 |
| OAK, 2016 | atelozumab (n=425) vs. docetaxel (n=425) | Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy | open label Parallel groups Sample size: 425/425 Primary endpoint: OS FU duration: minimum 19 months |
| IMpower150 (WT), 2018 | atezo + bev + C + P; (n=356) vs. bev + C + P (n=336) 3 arms : atezo 1200 mgþC AUC 6þP 200 mg/m2 (Arm A)
or atezo
þbev 15 mg/kg þC þ P (Arm B)
versus bev þ C þP (Arm C) IV q3w for 4 or 6 cycles per
investigator (INV) discretion,
then maintenance atezo, atezo þ bev or bev, respectively. | wild type chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (EGFR et ALK negative) | open label Parallel groups Sample size: 356/336 Primary endpoint: PFS, OS FU duration: |
| IMpower150 (Teff), 2018 | atezo + bev + C + P
(n=155) vs. bev + C + P
(n=129) 3 arms : atezo 1200 mgþC AUC 6þP 200 mg/m2 (Arm A)
or atezo
þbev 15 mg/kg þC þ P (Arm B)
versus bev þ C þP (Arm C) IV q3w for 4 or 6 cycles per
investigator (INV) discretion,
then maintenance atezo, atezo þ bev or bev, respectively.
| chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer and expression of a tumour T-effector gene signature (Teff) and EGFR et ALK negative (wild type)
| open label Parallel groups Sample size: 155/129 Primary endpoint: PFS, OS FU duration:
|
